Stem Cells and Stem Cell-Derived Factors for the Treatment of Inflammatory Bowel Disease with a Particular Focus on Perianal Fistulizing Disease: A Minireview on Future Perspectives.

Autor: Lightner AL; Surgery, Scripps Clinic, 10667 N Torrey Pines Rd, La Jolla, CA, 92037, USA. alightner@scripps.edu.; Molecular Medicine, Scripps Research Institute, La Jolla, USA. alightner@scripps.edu., Irving PM; Guy's and St Thomas' Hospital, London, UK.; King's College London, London, UK., Lord GM; University of Manchester, Manchester, UK., Betancourt A; Vitabolus Inc, San Diego, CA, USA.; Medicine, Tulane University School of Medicine, New Orleans, LA, USA.
Jazyk: angličtina
Zdroj: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2024 Jul; Vol. 38 (4), pp. 527-539. Date of Electronic Publication: 2024 Jun 25.
DOI: 10.1007/s40259-024-00661-6
Abstrakt: Inflammatory bowel disease remains a difficult disease to effectively treat, especially fistulizing Crohn's disease. Perianal fistulas in the setting of Crohn's disease remain an area of unmet need with significant morbidity in this patient population. Up to one third of Crohn's patients will have perianal fistulizing disease and current medical and surgical interventions are of limited efficacy. Thus, most patients experience significant morbidity, narcotic use, and loss of employment and end up with multiple surgical interventions. Mesenchymal stem cells (MSCs) have shown efficacy in phase 3 clinical trials, but considerable infrastructure challenges make MSCs limited with regard to scalability in clinical practice. Extracellular vesicles, being derived from MSCs and capturing the secretome functionality of MSCs, offer similar physiological utility regarding mechanism, while also providing an off the shelf regenerative medicine product that could be widely used in daily clinical practice.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: